<DOC>
	<DOCNO>NCT02808741</DOCNO>
	<brief_summary>Single dose comparison liquid solid formulation , follow study effect high fat breakfast . Evaluation multiple dose pharmacokinetics tolerability</brief_summary>
	<brief_title>Evaluation Immediate Release Tablet</brief_title>
	<detailed_description>The study split 2 part , Part 1 , ( A B ) , Part 2 . Part 1A Part 1A study single centre , open label , 2-way crossover healthy male female volunteer assess relative bioavailability single 360 mg dose ( 3 x 120mg tablet ) F901318 IR tablet formulation comparison 360 mg dose SDD suspension oral dosing . It plan 10 volunteer enrol Part 1A study . These 10 subject continue Part 1B study . There minimum washout 10 day dos provide volunteer . Following Part 1A two week period interim analysis safety pharmacokinetic data reviewed . In order ass dos within therapeutic range Part 1B , decision make use available data , whether dose F901318 IR tablet formulation alter . Dose alter amend number unit dose . Part 1B Following dose decision meeting data obtain Part 1A study review , select dose F901318 IR tablet formulation assess single centre , open label , 2-way crossover healthy male female volunteer . The select dose administer fed ( 30 minute follow FDA high fat meal ) fast state randomised fashion . . There minimum washout 10 day dos provide volunteer . Following Part 1B period period interim analysis safety pharmacokinetic data reviewed . In order ass dos within therapeutic range Part 2 , decision make use available data , dose F901318 IR formulation dose Part 2 . Dose altered amend number unit dose . It also determine dos Part 2 administer fed fast state . Part 2 In part 2 , dose ( ) anticipate yield therapeutic plasma concentration test 10-day period . This double blind placebo control , randomise , parallel group design 10 healthy male female subject , 8 take active compound 2 take placebo . In order mimic expect treatment schedule phase 2 trial , anticipate load dose give 1 2 day , follow daily twice daily dos study drug total 10 day . In part study , blood drawn safety pharmacokinetic evaluation . Adverse event , vital sign 12 lead ECGs monitor throughout . In Part 1 , Holter monitoring perform 12 hour dose . Part 2 , ECG Holter monitoring perform Days 1 10 .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<criteria>1 . Subjects healthy male females ethnic origin 18 55 year age weigh 50100 kg ( body mass index 18.032.0 kg/m2 inclusive ) . 2 . Females child bear potential must establish reliable form contraception negative pregnancy test screening . 3 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) . 4 . Subjects give write informed consent participate study abide study restriction . 1 . Subjects suitable vein multiple venepunctures/cannulation assess investigator screen 2 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 3 . Male female subject willing use appropriate contraception study 3 month last dose . 4 . Subjects receive prescribed systemic topical medication within 14 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>